gemcitabine has been researched along with Colorectal Neoplasms in 74 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 4 (5.41) | 18.2507 |
2000's | 38 (51.35) | 29.6817 |
2010's | 24 (32.43) | 24.3611 |
2020's | 8 (10.81) | 2.80 |
Authors | Studies |
---|---|
Bai, L; Li, H; Li, S; Tong, R; Yu, D; Zhang, Q | 1 |
Banciu, M; Berindan-Neagoe, I; Jurj, A; Rus, L; Sesarman, A; Stiufiuc, R; Tefas, LR; Toma, I; Tomuta, I | 1 |
Berres, ML; Gonzalez-Carmona, M; Kehmann, L; Keitel, V; Luedde, T; Modest, DP; Mohr, R; Roderburg, C; Strassburg, C; Trautwein, C; Venerito, M; Wree, A | 1 |
Gong, X; Li, Y; Li, YP; Wang, H; Xiong, FQ; Zhang, PC; Zhang, W; Zhang, Y; Zheng, C | 1 |
Abuhijjleh, RK; Al Saeedy, DY; Al-Abd, AM; Ashmawy, NS; Elhady, SS; Gouda, AE | 1 |
Jiang, Y; Liang, L; Ling, X; Shen, J; Sun, L; Zeng, X; Zhang, X | 1 |
Chen, D; Shen, W; Tan, X; Xu, T | 1 |
Allen, PJ; Balachandran, VP; Boerner, T; Boucher, TM; Cercek, A; Chapman, WC; Chou, JF; D'Angelica, MI; DeMatteo, RP; Diaz, LA; Do, RKG; Drebin, JA; Fields, RC; Gönen, M; Harding, JJ; Hauser, HF; Hawkins, WG; Jarnagin, WR; Kemeny, NE; Kingham, TP; Lim, KH; Lowery, MA; Majella Doyle, MB; Reidy-Lagunes, D; Saltz, L; Sanchez-Vega, F; Schultz, N; Strasberg, SM; Tan, BR; Vachharajani, N; Varghese, AM | 1 |
Bi, M; Hong, S; Li, S; Song, Y; Yan, Z | 1 |
Albrecht, MH; Gruber-Rouh, T; Hammerstingl, R; Lahrsow, M; Thompson, ZM; Vogl, TJ | 1 |
Junghanss, C; Maletzki, C; Nassar, I; Stenzel, J; Wiegele, L | 1 |
Barrett, AM; Chen, A; Doroshow, JH; Dull, AB; Hollingshead, MG; Kinders, RJ; Kummar, S; Lawrence, SM; Parchment, RE; Wilsker, DF | 1 |
Birnbaum, A; Cohen, RB; Denlinger, CS; Giles, J; He, AR; Hwang, J; Lewis, N; Moser, B; Mynderse, M; Niland, M; Plimack, ER; Sama, A; Sato, T; Walgren, R; Wallin, J; Zhang, W | 1 |
Bernard, A; Facy, O; Ghiringhelli, F; Ladoire, S; Lokiec, F; Magnin, G; Mordant, P; Pagès, PB | 1 |
Ahuja, N; Azad, NS; Danilova, L; Delmas, A; Herman, JG; Pelosof, L; Yerram, SR | 1 |
Alonso, MÁ; Jorge, M; Mendez, JC; Montes, AF; Pellón, ML; Quintero, G; Ramos, M; Reboredo, M; Romero, C; Salgado, M; Valladares-Ayerbes, M; Varela, S | 1 |
Anota, A; Auquier, P; Bascoul-Mollevi, C; Bonnetain, F; Borg, C; Chibaudel, B; Fiteni, F; Hamidou, Z; Paget-Bailly, S; Westeel, V | 1 |
Bestoso, E; Bianco, MT; Botta, C; Caraglia, M; Ciliberto, D; Conca, R; Correale, P; Cusi, MG; Fioravanti, A; Guglielmo, A; Guidelli, GM; Licchetta, A; Mantovani, G; Martino, E; Mini, E; Misso, G; Pastina, P; Pirtoli, L; Ridolfi, R; Rotundo, MS; Tagliaferri, P; Tassone, P | 1 |
Bhardwaj, TR; Malhotra, M; Rawal, RK; Sharma, AK; Sharma, R | 1 |
Andersen, RF; Jakobsen, A; Pallisgaard, N; Ploen, J; Spindler, KL | 1 |
Gao, RJ; Li, L; Li, Y; Liu, XJ; Qin, Y; Shao, RG; Zhen, YS | 1 |
Bang, YJ; Choi, IS; Han, SW; Im, SA; Kim, JH; Kim, TY; Kim, YJ; Lee, KH; Lee, KW; Oh, DY | 1 |
Cao, J; Huang, XE; Qian, ZY; Shi, L; Wu, XY; Xu, X | 1 |
Aftimos, P; Awada, A; Bahleda, R; Bourbouloux, E; Campone, M; Frenel, JS; Gombos, A; Soria, JC; Varga, A | 1 |
Chan, KW; Chen, H; Li, Y; Liu, G; Luo, L; McMahon, MT; van Zijl, PC; Vogelstein, B; Xu, J; Yadav, NN; Zhou, S | 1 |
Galmarini, CM; Kohli, E; Mitin, A; Vinogradov, SV; Warren, G; Zeman, A | 1 |
Balzer, JO; Eichler, K; Gruber, T; Hammerstingl, R; Vogl, TJ; Zangos, S | 1 |
Hoimes, C; Merl, M; Pham, T; Saif, MW | 1 |
Rajebi, MR; Saif, MW; Shahrokni, A | 1 |
Heller, G; Panageas, KS; Schrag, D; Sima, CS | 1 |
Majumdar, AP; Patel, BB | 1 |
Abajo, A; Bandres, E; Bitarte, N; Boni, V; Chopitea, A; Garcia-Foncillas, J; Ponz, M; Rodriguez, J; Zarate, R | 1 |
Bandres, E; Bitarte, N; Boni, V; Chopitea, A; Garcia-Foncillas, J; Hernández, A; Ponz-Sarvisé, M; Rodriguez, J; Zarate, R | 1 |
Ahn, JB; Hong, YS; Kim, SH; Kim, SY; Kim, TW; Lee, KH; Lee, SH; Park, SH; Park, YS; Shin, SJ | 1 |
Hotchkiss, S; Kaley, K; Penney, R; Saif, MW; Strimpakos, AS; Syrigos, KN | 1 |
Abbruzzese, A; Apollinari, S; Bestoso, E; Botta, C; Caraglia, M; Correale, P; Cusi, MG; Misso, G; Pastina, P; Sperlongano, P; Tagliaferri, P; Tassone, P | 1 |
Esaki, S; Goshima, F; Kimura, H; Murakami, S; Nishiyama, Y | 1 |
Höffken, K; Kliche, KO; Kubsch, K; Masri-Zada, R; Raida, M | 1 |
Brierre, JE; Buller, EJ; Cole, JL; Fontenot, MF; Lormand, NA; Rainey, JM; Rinaldi, DA; Stagg, MP | 1 |
Needle, MN | 1 |
Copeland, EM; Hochwald, SN; Lind, DS; MacKay, SL; Malaty, J; Moldawer, LL | 1 |
De Bruijn, EA; Friedel, G; Guetens, G; Hendriks, JM; Pauwels, B; Romijn, S; Van Putte, BP; Van Schil, PE | 1 |
Abbruzzese, A; Caraglia, M; Ceciarini, F; Correale, P; Francini, G; Giorgi, G; Guarnieri, A; Marsili, S; Messinese, S; Micheli, L; Nencini, C; Neri, A; Petrioli, R; Piccolomini, A; Prete, SD; Vuolo, G | 1 |
Baker, JH; Huxham, LA; Kyle, AH; Minchinton, AI; Nykilchuk, LK | 1 |
Cree, IA; Di Nicolantonio, F; Glaysher, S; Johnson, P; Knight, LA; Mercer, S; Sharma, S; Whitehouse, P | 1 |
Berger, MR; Eyol, E; Rodenbach, M; Seelig, MH | 1 |
Haller, DG | 1 |
Hendriks, JM; Pauwels, B; Romijn, S; Van Putte, BP; Van Schil, PE; Vermorken, JB | 1 |
Aquino, A; Bonmassar, E; Correale, P; Cusi, MG; Del Vecchio, MT; Ferrari, F; Francini, G; Giorgi, G; Intrivici, C; Marsili, S; Micheli, L; Nencini, C; Placa, ML; Tsang, KY | 1 |
Cheng, YC; Lam, W; Leung, CH; Park, SY | 1 |
Gasparro, S; La Cesa, A; Santini, D; Schiavon, G; Tonini, G; Vincenzi, A; Vincenzi, B | 1 |
Parker, WB; Someya, H; Thottassery, JV; Westbrook, L | 1 |
De Greef, K; Hendriks, JM; Romijn, S; Van Putte, BP; Van Schil, PE | 1 |
Du, W; Posner, M; Schmidt, H; Shafaee, Z; Weichselbaum, R | 1 |
Avritscher, EB; Bekele, BN; Cooksley, CD; Elting, LS; Jones, JA; Michelet, M | 1 |
Choi, YH; Chung, HC; Jeung, HC; Jung, JJ; Kim, TS; Kwon, WS; Lee, JO; Park, KH; Rha, SY | 1 |
Barzon, L; Cartei, G; Nadai, M; Palù, G; Palumbo, M; Richter, SN; Trestin, A | 1 |
Lahans, T | 1 |
Kibble, A | 1 |
André, T; Blanchard, P; Huguet, F | 1 |
Bauer, RW; Eichler, K; Selby, JB; Vogl, TJ; Zangos, S | 1 |
Chang, AY; Fong, FK; Hsin, KW; Lim, R; Lopes, G; Wong, J | 1 |
Csoka, K; Larsson, R; Liliemark, J; Nygren, P | 1 |
Chang, E; Hahn, TM; Hertel, LW; Lawrence, TS; Shewach, DS | 1 |
Fukuoka, M; Furuse, K; Hasegawa, K; Hirabayashi, K; Nakajima, H; Niitani, H; Noda, K; Ogura, T; Taguchi, T | 1 |
Beger, HG; Blatter, J; Butzer, U; Kornmann, M; Link, KH | 1 |
Bregman, D; Manalo, J; Mani, S | 1 |
Carpini, RD; Fedier, A; Fink, D; Haller, U; Schwarz, VA; Walt, H | 1 |
Copeland, EM; Hebig, P; Hochwald, SN; Lind, DS; Mackay, S; Malaty, J; Mishra, G; Moldawer, LL; Rekkas, S | 1 |
Brunson, CY; Green, MR; Kneuper-Hall, R; Lal, A; Rocha Lima, CM; Urbanic, JJ | 1 |
Coudray, AM; Faivre, S; Gespach, C; Louvet, C; Raymond, E | 1 |
Alvarez, E; Bergman, AM; Eriksson, S; Kroep, JR; Loves, WJ; Peters, GJ; Pinedo, HM; Talianidis, I; van der Wilt, CL; van Groeningen, CJ | 1 |
Bertucci, D; Kindler, HL; Ratain, MJ; Schilsky, RL; Vogelzang, NJ | 1 |
Abbruzzese, JL; Daugherty, K; Moore, DF; Pazdur, R; Tarassoff, P | 1 |
9 review(s) available for gemcitabine and Colorectal Neoplasms
Article | Year |
---|---|
Is there a palliative benefit of gemcitabine plus fluoropyrimidines in patients with refractory colorectal cancer? A review of the literature previously presented: poster at the 2008 Gastrointestinal Cancer Symposium (Abstract No. 512).
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Maximum Tolerated Dose; Palliative Care; Treatment Outcome | 2009 |
Synergistic role of curcumin with current therapeutics in colorectal cancer: minireview.
Topics: Adenoma; Animals; Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; Curcumin; Deoxycytidine; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2009 |
Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Cisplatin; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Eruptions; Drug Hypersensitivity; Drug Interactions; Gemcitabine; Head and Neck Neoplasms; Humans; Irinotecan; Pancreatic Neoplasms | 2002 |
Recent updates in the clinical use of platinum compounds for the treatment of gastrointestinal cancers.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Esophageal Neoplasms; Gastrointestinal Neoplasms; Gemcitabine; Humans; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Platinum Compounds; Stomach Neoplasms | 2004 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Colorectal Neoplasms; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Humans; Incidence; Lung Neoplasms; Lymphoma, Non-Hodgkin; Mucositis; Neoplasms; Prednisone; Radiotherapy; Severity of Illness Index; Stomatitis; Taxoids; Vinblastine; Vincristine; Vinorelbine | 2006 |
[Gemcitabine and digestive carcinomas].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Cisplatin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Digestive System Neoplasms; Esophageal Neoplasms; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Organoplatinum Compounds; Pancreatic Neoplasms; Pyridines; Stomach Neoplasms | 2007 |
Novel combinations with oxaliplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Randomized Controlled Trials as Topic; Thiophenes | 2000 |
Beyond pancreatic cancer: irinotecan and gemcitabine in solid tumors and hematologic malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Gemcitabine; Hematologic Neoplasms; Humans; Irinotecan; Lung Neoplasms; Lymphoma, Non-Hodgkin; Pancreatic Neoplasms | 2001 |
[Preclinical studies of oxaliplatin in combination chemotherapy].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Drug Interactions; Drug Screening Assays, Antitumor; Fluorouracil; Gemcitabine; Humans; Mice; Models, Biological; Organoplatinum Compounds; Oxaliplatin; Tumor Cells, Cultured | 2001 |
18 trial(s) available for gemcitabine and Colorectal Neoplasms
Article | Year |
---|---|
Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Frontotemporal Dementia; Gemcitabine; Humans; Irinotecan; Prospective Studies; Trifluridine | 2023 |
Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Colorectal Neoplasms; Deoxycytidine; Female; Floxuridine; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Oxaliplatin; Treatment Outcome | 2020 |
First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Proliferation; Cetuximab; Cholangiocarcinoma; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Indazoles; Male; Middle Aged; Neoplasm Staging; Niacinamide; Protein Kinase Inhibitors; Ramucirumab; Squamous Cell Carcinoma of Head and Neck | 2019 |
Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: the GOLFIG-2 multicentric open-label randomized phase
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-2; Leucovorin; Lymphocytes, Tumor-Infiltrating; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2014 |
Gemcitabine and capecitabine for heavily pre-treated metastatic colorectal cancer patients--a phase II and translational research study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Translational Research, Biomedical | 2014 |
Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Republic of Korea; Salvage Therapy; Tegafur; Treatment Outcome; Uracil | 2014 |
Association of RRM1 -37A>C polymorphism with clinical outcome in colorectal cancer patients treated with gemcitabine-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Blotting, Western; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Gemcitabine; Genotype; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Polymorphism, Genetic; Retrospective Studies; Ribonucleoside Diphosphate Reductase; RNA, Small Interfering; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2011 |
Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Survival Rate; Thrombocytopenia | 2012 |
Immune-modulating effects of the newest cetuximab-based chemoimmunotherapy regimen in advanced colorectal cancer patients.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Case-Control Studies; Cell Line, Tumor; Cetuximab; Colorectal Neoplasms; Dendritic Cells; Deoxycytidine; Drug Administration Schedule; ErbB Receptors; Female; Fluorouracil; Gemcitabine; Humans; Immunomodulation; Immunotherapy; Interleukin-2; Irinotecan; Killer Cells, Natural; Male; Middle Aged; Recombinant Proteins; T-Lymphocyte Subsets | 2012 |
Chronomodulated chemotherapy in metastatic gastrointestinal cancer combining 5-FU and sodium folinate with oxaliplatin, irinotecan or gemcitabine: the Jena experience in 79 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Folic Acid; Gastrointestinal Neoplasms; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Stomach Neoplasms | 2002 |
Phase I trial of gemcitabine, administered as a standard and constant dose-rate infusion, in combination with paclitaxel in patients with advanced solid tumors (LOA-2).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Urologic Neoplasms | 2002 |
A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2004 |
Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer
Topics: Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colonic Neoplasms; Colorectal Neoplasms; Cytotoxicity, Immunologic; Deoxycytidine; Disease Progression; Female; Flow Cytometry; Fluorouracil; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunotherapy; Infusions, Intravenous; Interleukin-2; Leucovorin; Male; Organoplatinum Compounds; Oxaliplatin; T-Lymphocytes, Regulatory; Thymidylate Synthase; Treatment Outcome | 2005 |
Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Time Factors | 2006 |
Phase II trial of 5-fluorouracil/leucovorin/gemcitabine/cisplatin as second-line treatment in patients with metastatic or recurrent colorectal carcinoma: a cancer therapeutics research group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Survival Analysis | 2007 |
[An early phase II study of gemcitabine hydrochloride (LY 188011). Gemcitabine Cooperative Study Group for Early Phase II].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Ovarian Neoplasms; Stomach Neoplasms; Uterine Cervical Neoplasms | 1996 |
Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasms; Neutropenia; Pancreatic Neoplasms; Stomatitis; Treatment Outcome | 2002 |
Phase II study of gemcitabine in advanced colorectal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged | 1992 |
47 other study(ies) available for gemcitabine and Colorectal Neoplasms
Article | Year |
---|---|
Self-Delivery Janus-Prodrug for Precise Immuno-Chemotherapy of Colitis-Associated Colorectal Cancer.
Topics: Animals; Antineoplastic Agents; Biocompatible Materials; Budesonide; Cell Line; Colitis-Associated Neoplasms; Colorectal Neoplasms; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Materials Testing; Mice; Mice, Inbred BALB C; Molecular Dynamics Simulation; Molecular Structure; Prodrugs | 2022 |
Co-delivery of gemcitabine and salinomycin in PEGylated liposomes for enhanced anticancer efficacy against colorectal cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Colorectal Neoplasms; Deoxycytidine; Gemcitabine; Humans; Liposomes; Polyethylene Glycols | 2023 |
Gemcitabine-loaded synthetic high-density lipoprotein preferentially eradicates hepatic monocyte-derived macrophages in mouse liver with colorectal cancer metastases.
Topics: Animals; Antigens, Neoplasm; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Colorectal Neoplasms; Gemcitabine; Lipoproteins, HDL; Liver Neoplasms; Macrophages; Mice; Tumor Microenvironment | 2023 |
Chemomodulatory Effect of the Marine-Derived Metabolite "Terrein" on the Anticancer Properties of Gemcitabine in Colorectal Cancer Cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Gemcitabine; Humans | 2023 |
Comprehensive analysis identifies novel targets of gemcitabine to improve chemotherapy treatment strategies for colorectal cancer.
Topics: Biomarkers; Cell Line; Colorectal Neoplasms; Dasatinib; Gemcitabine; Humans | 2023 |
Targeting SREBP1 chemosensitizes colorectal cancer cells to gemcitabine by caspase-7 upregulation.
Topics: Adult; Aged; Antineoplastic Agents; Caspase 7; Cell Line, Tumor; Colorectal Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Sterol Regulatory Element Binding Protein 1; Up-Regulation; Young Adult | 2019 |
LncRNA AGAP2-AS1 augments cell viability and mobility, and confers gemcitabine resistance by inhibiting miR-497 in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinogenesis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Middle Aged; Oncogenes; Prognosis; RNA, Long Noncoding; Up-Regulation | 2020 |
Survival of patients with non-resectable, chemotherapy-resistant colorectal cancer liver metastases undergoing conventional lipiodol-based transarterial chemoembolization (cTACE) palliatively versus neoadjuvantly prior to percutaneous thermal ablation.
Topics: Ablation Techniques; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Cisplatin; Colonic Neoplasms; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Ethiodized Oil; Female; Gemcitabine; Humans; Hyperthermia, Induced; Irinotecan; Laser Therapy; Liver Neoplasms; Male; Microwaves; Middle Aged; Mitomycin; Neoadjuvant Therapy; Palliative Care; Prognosis; Rectal Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2018 |
Chemo-immunotherapy improves long-term survival in a preclinical model of MMR-D-related cancer.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cancer Vaccines; Cell Line, Tumor; Colorectal Neoplasms; Cyclophosphamide; Dendritic Cells; Deoxycytidine; Gastrointestinal Neoplasms; Gemcitabine; Immunotherapy; Mice; Myeloid-Derived Suppressor Cells; Neoplastic Syndromes, Hereditary; Spleen; T-Lymphocytes, Regulatory | 2019 |
Evaluation of Pharmacodynamic Responses to Cancer Therapeutic Agents Using DNA Damage Markers.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Cell Cycle Proteins; Clofarabine; Colorectal Neoplasms; Deoxycytidine; DNA Damage; DNA Repair; Gemcitabine; HCT116 Cells; Histones; HT29 Cells; Humans; Mice; Mice, Nude; Nuclear Proteins; Rad51 Recombinase; Topotecan; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Isolated lung perfusion as an adjuvant treatment of colorectal cancer lung metastases: a preclinical study in a pig model.
Topics: Analysis of Variance; Animals; Antineoplastic Agents; Cell Line, Tumor; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Hemodynamics; Humans; Lung Neoplasms; Perfusion; Swine; Treatment Outcome; Vasoconstriction | 2013 |
CHFR silencing or microsatellite instability is associated with increased antitumor activity of docetaxel or gemcitabine in colorectal cancer.
Topics: Animals; Antineoplastic Agents; Base Sequence; Cell Cycle Proteins; Cell Line, Tumor; Colorectal Neoplasms; Deoxycytidine; DNA Methylation; DNA Primers; Docetaxel; Female; Gemcitabine; Gene Silencing; Humans; Mice; Microsatellite Instability; Neoplasm Proteins; Poly-ADP-Ribose Binding Proteins; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction; Taxoids; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2014 |
Gemcitabine and capecitabine as third- or later-line therapy for refractory advanced colorectal cancer: a retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Retrospective Studies | 2013 |
Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization?
Topics: Adult; Aged; Breast Neoplasms; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Gemcitabine; Health Services Needs and Demand; Health Status; Humans; Longitudinal Studies; Middle Aged; Pancreatic Neoplasms; Quality of Life; Response Evaluation Criteria in Solid Tumors | 2015 |
Design, synthesis and ex-vivo release studies of colon-specific polyphosphazene-anticancer drug conjugates.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colon; Colorectal Neoplasms; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Drug Design; Gemcitabine; HT29 Cells; Humans; Methotrexate; Organophosphorus Compounds; Polymers; Rats | 2014 |
MMP-2/9-oriented combinations enhance antitumor efficacy of EGFR/HER2-targeting fusion proteins and gemcitabine.
Topics: Animals; Antibodies; Antineoplastic Agents; Cell Line, Tumor; Colorectal Neoplasms; Deoxycytidine; Doxycycline; Drug Therapy; Enediynes; ErbB Receptors; Female; Gemcitabine; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Molecular Targeted Therapy; Neoplasms, Experimental; Recombinant Fusion Proteins; Treatment Outcome; Xenograft Model Antitumor Assays | 2014 |
A predictive model for evaluating responsiveness to pemetrexed treatment in patients with advanced colorectal cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carboplatin; Cisplatin; Colorectal Neoplasms; Cyclobutanes; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Logistic Models; Male; Middle Aged; Multivariate Analysis; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Prognosis | 2014 |
An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carbazoles; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphoma, Mantle-Cell; Male; Melanoma; Middle Aged; Neoplasms; Ovarian Neoplasms; Phthalimides; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases | 2016 |
CEST theranostics: label-free MR imaging of anticancer drugs.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Contrast Media; Deoxycytidine; Drug Delivery Systems; Female; Fluorescence; Gemcitabine; Humans; Image Interpretation, Computer-Assisted; Immunoenzyme Techniques; Liposomes; Magnetic Resonance Imaging; Mice; Mice, Inbred BALB C; Mice, Nude; Theranostic Nanomedicine; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Polymeric nanogels containing the triphosphate form of cytotoxic nucleoside analogues show antitumor activity against breast and colorectal cancer cell lines.
Topics: Animals; Antineoplastic Agents; Arabinofuranosylcytosine Triphosphate; Breast Neoplasms; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Proliferation; Chemistry, Pharmaceutical; Colorectal Neoplasms; Cytarabine; Deoxycytidine; Drug Carriers; Drug Screening Assays, Antitumor; Flow Cytometry; Gemcitabine; Humans; Mice; Nanogels; Nucleosides; Polyethylene Glycols; Polyethyleneimine; Polymers; Polyphosphates | 2008 |
Repeated transarterial chemoembolization in the treatment of liver metastases of colorectal cancer: prospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Mitomycin; Palliative Care; Prospective Studies; Survival Rate; Tomography, Spiral Computed | 2009 |
Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: A challenge or a dilemma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Foot Dermatoses; Gemcitabine; Hand Dermatoses; Humans; Liver Neoplasms; Male; Middle Aged; Polymorphism, Genetic; Thymidylate Synthase; Treatment Outcome | 2009 |
Analytical strategies for characterizing chemotherapy diffusion with patient-level population-based data.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Deoxycytidine; Diffusion of Innovation; Drug Approval; Drug Utilization; Gemcitabine; Humans; Models, Statistical; Pancreatic Neoplasms; Quality of Health Care; SEER Program; United States; United States Food and Drug Administration | 2010 |
Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Gemcitabine; Genotype; Humans; Irinotecan; Neoplasm Metastasis; Pharmacogenetics; Survival Analysis; Time Factors; Vascular Endothelial Growth Factor A | 2010 |
The efficacy of gemcitabine as salvage treatment in patients with refractory advanced colorectal cancer (CRC): a single institution experience.
Topics: Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Salvage Therapy | 2011 |
Enhanced antitumoral activity of oncolytic herpes simplex virus with gemcitabine using colorectal tumor models.
Topics: Animals; Antigen Presentation; Antimetabolites, Antineoplastic; Chlorocebus aethiops; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Herpes Simplex; Injections, Intralesional; Interferon-gamma; Mice; Mice, Inbred BALB C; Oncolytic Virotherapy; Simplexvirus; Spleen; T-Lymphocytes; Vero Cells | 2013 |
Antineoplastic therapy in colorectal cancer through proteasome inhibition.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Caspase 3; Caspases; Colorectal Neoplasms; Cysteine Endopeptidases; Deoxycytidine; DNA, Neoplasm; Electrophoretic Mobility Shift Assay; Enzyme Inhibitors; Enzyme Precursors; Gemcitabine; Gene Transfer Techniques; Humans; Leupeptins; Luciferases; Multienzyme Complexes; NF-kappa B; Proteasome Endopeptidase Complex; Rats; Transcriptional Activation; Tumor Cells, Cultured; Up-Regulation | 2003 |
Isolated lung perfusion with gemcitabine in a rat: pharmacokinetics and survival.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Survival; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Deoxycytidine; Gemcitabine; Infusions, Intravenous; Lung Neoplasms; Male; Models, Animal; Rats; Survival Analysis; Tumor Cells, Cultured | 2003 |
Microregional effects of gemcitabine in HCT-116 xenografts.
Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Deoxycytidine; Female; Gemcitabine; HCT116 Cells; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2004 |
The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours.
Topics: Adenocarcinoma; Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gefitinib; Gemcitabine; Humans; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Quinazolines; Sarcoma; Skin Neoplasms; Stomach Neoplasms; Uveal Neoplasms | 2004 |
Combination treatment of CC531-lac-Z rat liver metastases by chemoembolization with pemetrexed disodium and gemcitabine.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Chemoembolization, Therapeutic; Colorectal Neoplasms; Combined Modality Therapy; Death; Deoxycytidine; Disease Models, Animal; Gemcitabine; Glutamates; Guanine; Liver Neoplasms; Male; Neoplasm Metastasis; Pemetrexed; Rats; Rats, Inbred Strains | 2005 |
Combination chemotherapy with gemcitabine with isolated lung perfusion for the treatment of pulmonary metastases.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; In Vitro Techniques; Inhibitory Concentration 50; Lung Neoplasms; Male; Melphalan; Rats; Rats, Inbred Strains; Tumor Cells, Cultured | 2005 |
Apurinic/apyrimidinic endonuclease-1 protein level is associated with the cytotoxicity of L-configuration deoxycytidine analogs (troxacitabine and beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine) but not D-configuration deoxycytidine analogs (gemcit
Topics: Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Cytosine; Deoxycytidine; Dioxolanes; DNA-(Apurinic or Apyrimidinic Site) Lyase; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; RNA, Small Interfering; Transfection | 2006 |
c-Abl-independent p73 stabilization during gemcitabine- or 4'-thio-beta-D-arabinofuranosylcytosine-induced apoptosis in wild-type and p53-null colorectal cancer cells.
Topics: Apoptosis; Arabinonucleosides; Carcinoma; Caspase 3; Caspases; Colorectal Neoplasms; Deoxycytidine; DNA-Binding Proteins; Gemcitabine; Gene Deletion; Genes, Tumor Suppressor; Humans; Nuclear Proteins; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-abl; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Up-Regulation | 2006 |
Toxicity and efficacy of isolated lung perfusion with gemcitabine in a rat model of pulmonary metastases.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Gemcitabine; Lung; Lung Neoplasms; Male; Random Allocation; Rats; Ribonucleotide Reductases; Treatment Outcome | 2006 |
Cyclopamine increases the cytotoxic effects of paclitaxel and radiation but not cisplatin and gemcitabine in Hedgehog expressing pancreatic cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; HCT116 Cells; Hedgehog Proteins; Humans; Paclitaxel; Pancreatic Neoplasms; Radiation, Ionizing; Time Factors; Veratrum Alkaloids | 2006 |
Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Colorectal Neoplasms; DCMP Deaminase; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; In Vitro Techniques; Inhibitory Concentration 50; Lung Neoplasms; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Ribonucleoside Diphosphate Reductase; Stomach Neoplasms; Tumor Suppressor Proteins | 2006 |
In vitro basis for schedule-dependent interaction between gemcitabine and topoisomerase-targeted drugs in the treatment of colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Deoxycytidine; DNA Topoisomerases; Drug Administration Schedule; Drug Evaluation, Preclinical; Drug Interactions; Enzyme Inhibitors; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Topoisomerase Inhibitors; Treatment Outcome | 2006 |
Integrating Chinese and conventional medicine in colorectal cancer treatment.
Topics: Adenocarcinoma; Antineoplastic Agents; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Drugs, Chinese Herbal; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Medicine, Chinese Traditional; Middle Aged | 2007 |
American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 3.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Biomedical Research; Breast Neoplasms; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Male; Molecular Structure; Neoplasms; Organoplatinum Compounds; Pancreatic Neoplasms; Piperidines; Prednisolone; Prostatic Neoplasms; Quinazolines; Treatment Outcome | 2007 |
Palliative hepatic intraarterial chemotherapy (HIC) using a novel combination of gemcitabine and mitomycin C: results in hepatic metastases.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Breast Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Injections, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Mitomycin; Palliative Care; Treatment Outcome | 2008 |
Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Cladribine; Colorectal Neoplasms; Cytarabine; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; In Vitro Techniques; Leukemia; Lung Neoplasms; Lymphoma; Ribonucleotide Reductases; Tumor Cells, Cultured; Urogenital Neoplasms | 1995 |
Metabolism of 2',2'-difluoro-2'-deoxycytidine and radiation sensitization of human colon carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Deoxycytidine; Deoxyribonucleotides; DNA, Neoplasm; Gemcitabine; Humans; Kinetics; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 1994 |
Pre-clinical evaluation of the activity of gemcitabine as a basis for regional chemotherapy of pancreatic and colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Cell Division; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Gemcitabine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Kinetics; Liver Neoplasms; Male; Middle Aged; Neoplastic Stem Cells; Pancreatic Neoplasms; Tumor Cells, Cultured | 2000 |
Resistance to topoisomerase poisons due to loss of DNA mismatch repair.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Base Pair Mismatch; Breast Neoplasms; Carrier Proteins; Colorectal Neoplasms; Deoxycytidine; DNA Repair; DNA-Binding Proteins; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Enzyme Inhibitors; Epirubicin; Female; Gemcitabine; Humans; Intercalating Agents; Mitoxantrone; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Proteins; Nuclear Proteins; Paclitaxel; Proto-Oncogene Proteins; Taxoids; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2001 |
Nuclear factor-kappa B is upregulated in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Caspase 3; Caspases; Colon; Colorectal Neoplasms; Cysteine Proteinase Inhibitors; Deoxycytidine; DNA; Gemcitabine; Humans; Intestinal Mucosa; Leupeptins; NF-kappa B; Protein Binding; Rectum; Tumor Cells, Cultured | 2001 |
The role of deoxycytidine kinase in gemcitabine cytotoxicity.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Colorectal Neoplasms; Deoxycytidine; Deoxycytidine Kinase; Dexamethasone; Enzyme Inhibitors; Female; Gemcitabine; Gene Expression; Glucocorticoids; HL-60 Cells; Humans; Protein Kinase C; Ribonucleotide Reductases; RNA, Messenger; Staurosporine; Tumor Cells, Cultured; U937 Cells | 2000 |